SRX.AX - Sirtex Medical Limited

ASX - ASX Delayed price. Currency in AUD
27.40
-0.36 (-1.30%)
At close: 4:10PM AEDT
Stock chart is not supported by your current browser
Previous close27.76
Open27.60
Bid27.35 x 10700
Ask27.40 x 2100
Day's range27.40 - 27.78
52-week range10.45 - 27.82
Volume315,368
Avg. volume591,422
Market cap1.528B
BetaN/A
PE ratio (TTM)N/A
EPS (TTM)-0.46
Earnings dateN/A
Forward dividend & yield0.30 (1.67%)
Ex-dividend date2017-09-26
1y target est25.50
  • AAP18 days ago

    'No surprise' at huge Sirtex takeover bid

    The head of Sirtex Medical says he is not surprised US suitor Varian Medical offered a 49 per cent share price premium in its $1.6 billion takeover offer for the Australian cancer treatment developer . Sirtex CEO Andrew McLean says he was "not at all" surprised by Varian's offer, which at $28 for each Sirtex share represents a 49 per cent mark-up on the January 29 closing price of $18.83, and a 60 per cent premium to the average price over January. "Sirtex is a wonderful business with strong prospects," Mr McLean said on Wednesday.

  • AAP18 days ago

    Sirtex soars on Varian takeover offer

    Shares in liver cancer treatment developer Sirtex Medical have soared, gaining almost 50 per cent after resuming trading on Wednesday following news that US cancer care firm Varian has agreed to pay $1.6 ...

  • AAP18 days ago

    Sirtex agrees to $1.6b US takeover

    Australian-based liver cancer treatment developer Sirtex Medical has agreed to a $1.6 billion takeover offer from US company Varian. Sirtex distributes a radiation therapy to more than 1,090 hospitals in over 40 countries, and currently has a market value of $1.05 billion. Varian, which is listed on the New York Stock Exchange with a market value of $US11.8 billion, is based in California and develops radiotherapy and screening technology to treat cancer.

  • Sirtex Medical Limited Board recommends takeover proposal
    Motley Fool18 days ago

    Sirtex Medical Limited Board recommends takeover proposal

    The Sirtex Medical Limited (ASX:SRX) board have recommended the takeover proposal.

  • Varian to Buy Sirtex for $1.3 Billion to Add Cancer Drugs
    Bloomberg19 days ago

    Varian to Buy Sirtex for $1.3 Billion to Add Cancer Drugs

    Varian Medical Systems Inc. agreed to buy Australia’s Sirtex Medical Ltd. for about A$1.6 billion ($1.3 billion) in a bid by the U.S. company to add radiation medicine to its portfolio for cancer treatments....

  • Is Sirtex Medical Limited about to make a major acquisition?
    Motley Fool19 days ago

    Is Sirtex Medical Limited about to make a major acquisition?

    Sirtex Medical Ltd (ASX:SRX) just entered a trading halt pending a 'potential material corporate transaction.'

  • AAP19 days ago

    Sirtex shares in halt ahead of deal

    Shares in Sirtex Medical have been placed in a trading halt ahead of what the cancer treatment specialist called a "potential material corporate transaction". The liver cancer treatment developer, which booked a $26.3 million loss in 2016/17 after writedowns and failed clinical trials, this month said it expects underlying first-half earnings of $34 million - a 16 per cent improvement on the previous first half.

  • These 3 ASX shares just hit 52-week highs
    Motley Fool25 days ago

    These 3 ASX shares just hit 52-week highs

    The Flight Centre Travel Group Ltd (ASX:FLT) share price is one of three that hit a 52-week high on Tuesday. Here's why…

  • ALL ORDINARIES finishes lower Wednesday: 9 shares you missed
    Motley Foollast month

    ALL ORDINARIES finishes lower Wednesday: 9 shares you missed

    The S&P/ASX 200 (Index:^AXJO)(ASX:XJO) and ALL ORDINARIES (Index:^AXAO) (ASX:XAO) finished lower on Wednesday.

  • Sirtex shares jump on improved earnings
    AAPlast month

    Sirtex shares jump on improved earnings

    Sirtex Medical shares have surged after the liver cancer treatment specialist flagged improved first-half earnings and a turnaround in second-half sales. Sales of the company's SIR-Spheres microspheres - a product used to deliver medication to cancer sites inside the body - were flat in the first half but Sirtex CEO Andrew McLean, who took up his role in May, said the company expects higher sales in the second half of 2017/18.

  • Why the Sirtex Medical Limited share price just jumped 13% to a 52-week high
    Motley Foollast month

    Why the Sirtex Medical Limited share price just jumped 13% to a 52-week high

    The Sirtex Medical Limited (ASX:SRX) share price jumped 13% to a 52-week high today, following an earnings update.

  • Why the Sirtex Medical Limited share price jumped 16% on earnings guidance
    Motley Foollast month

    Why the Sirtex Medical Limited share price jumped 16% on earnings guidance

    The Sirtex Medical Limited (ASX:SRX) share price jumped 16% after an earnings update this morning.

  • Is IMF Bentham Ltd a buy at this share price?
    Motley Fool2 months ago

    Is IMF Bentham Ltd a buy at this share price?

    IMF Bentham Ltd (ASX:IMF) has made a name for itself trying claw cash back from companies for investors. But should you invest in IMF?  

  • Sirtex Q1 revenue down, but profit up
    AAP4 months ago

    Sirtex Q1 revenue down, but profit up

    Liver cancer treatments group Sirtex Medical says dosage sales in the first three months of the current financial year have been flat and sales revenue is down because of adverse currency movements, but profit is improving. Chief executive Andrew McClean has told shareholders that the first quarter is showing "some early favourable results" from the company's efforts to improve efficiency and productivity. Sirtex's main product is a medical device called SIR-Spheres Y-90 resin microspheres, to treat liver cancer.

  • AAP4 months ago

    Sirtex first-quarter sales revenue down

    Liver cancer treatments group Sirtex Medical says revenue for the first quarter of 2017/18 has dipped as a result of flat unit sales and adverse currency movements. Sirtex CEO Andrew McClean has told the company's annual general meeting that the first quarter is showing "some early favourable results", dose sales of cancer treatments are flat on the corresponding previous quarter and sales revenue is down about five per cent after currency effects.

  • Business Wire9 months ago

    Sirtex Medical Inc. Provides Update on SIR-Spheres® Y-90 Resin Microspheres in Combination with First-Line Chemotherapy for Patients with Unresectable Metastatic Colorectal Cancer (mCRC)

    WOBURN, Mass.--(BUSINESSWIRE)-- Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX.AX - News), a leading manufacturer of targeted liver cancer therapies, today announced the Combined FOXFIRE Analysis that evaluated SIR-Spheres Y-90 resin microspheres in combination with chemotherapy in patients with mCRC did not improve overall survival compared to chemotherapy alone. The Combined FOXFIRE Analysis is comprised of data from the SIRFLOX study first presented in 2015 and data from two new studies – FOXFIRE and FOXFIRE-Global.